Product Cart
| Cat#: | P-1001-2-EP |
| Quantity: | 80 rxns |
| Price: | 239 € |
| Supplier: | Epigentek |
Fast and Efficient Bisulfite Modification
• The fastest procedure available on the market, which can be completed within 1 hour and 55 minutes
• Completely converts unmethylated cytosine into uracil - modified DNA > 99.98%
• The lowest degradation of DNA in the modification process - more than 90% of DNA loss can be prevented
• The lowest requirement of starting DNA for modification - only 50 pg or 20 cells
• Extremely simple, reliable, and consistent modification conditions
The Methylamp DNA Modification Kit is a complete set of essential components which enables DNA methylation analysis using Epigentek´s uniquely simplified and streamlined bisulfite method. The entire procedure can be completed within a mere 1 hour and 55 minutes and produces far superior results than any other commercially available kits. The resulting modified DNA is suitable for MS-PCR, real time MS-PCR, methylation sequencing, and pyrosequencing, as well as methylation microarray.
Procedure
The Methylamp DNA Modification Kit contains all reagents required for bisulfite conversion on a DNA sample. DNA is chemically denatured to allow bisulfite reagent to react specifically with single-stranded DNA, thereby deaminating cytosine and creating a uracil residue. The unique DNA protection reagents contained in the modification buffer prevent the chemical and thermophilic degradation of DNA during bisulfite treatment. The non-toxic modified DNA capture buffer enables DNA to bind tightly to the column filter, thus residual sodium bisulfite and salts can be effectively removed and clean modified DNA eluted.
References
Torrisani, J. et al. (2008) Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology 149(6): 3137-47.
Ushmorov A. et al. (2008) ABF-1 is frequently silenced by promoter methylation in follicular lymphoma, diffuse large B-cell lymphoma and Burkitt´s lymphoma. Leukemia 22(10):1942-4.
Olsson, M. et al. (2007) Regulation and expression of human CYP7B1 in prostate: Overexpression of CYP7B1 during progression of prostatic adenocarcinoma. Prostate 67(13): 1439-46.
Tokita, T. et al. (2007) Methylation status of the SOCS3 gene in human malignant melanomas. International Journal of Oncology 30(3): 689-94.
Mizoguchi, Y. et al. (2007). Steroid-Dependent ACTH-Produced Thymic Carcinoid: Regulation of POMC Gene Expression by Cortisol via Methylation of Its Promoter Region. Hormone Research 67(5): 257-62.
Cheng, S.H. et al. (2007) 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood 109(5):2089-99.
Li, K.K.W. et al. (2006) EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. International Journal of Cancer 120(4): 947-50.
Tong, Y.K. et al. (2006). Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. Clin. Chem. 52(12): 2182-3.
A high-throughput version in 96-well format (Cat# P-1008-EP) as well as a fast DNA modification version using heating process (Cat# P-1010-EP) are also available.
